Finance

Lists
Why is GLAXO up 2.72%?
Dive Deeper
GLAXO:NSE
GlaxoSmithKline Pharmaceuticals Ltd
₹2,710.00
+2.72%
(+71.80) 1D
Nov 19, 3:30:00 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for GLAXO...
Open
₹2,635.30
High
₹2,719.90
Low
₹2,595.90
Mkt. cap
459.58B
Avg. vol.
91.52K
Volume
123.43K
Dividend
2.10%
Quarterly dividend
₹14.25
Ex-dividend date
May 29, 2026
P/E ratio
40.04
52-wk high
₹3,120.70
52-wk low
₹2,088.10
EPS
₹67.68
Shares outstanding
169.41M
No. of employees
3K
Open
₹2,635.30
High
₹2,719.90
Low
₹2,595.90
Mkt. cap
459.58B
Avg. vol.
91.52K
Volume
123.43K
Dividend
2.10%
Quarterly dividend
₹14.25
Ex-dividend date
May 29, 2026
P/E ratio
40.04
52-wk high
₹3,120.70
52-wk low
₹2,088.10
EPS
₹67.68
Shares outstanding
169.41M
No. of employees
3K
News stories
From web sources and news partners
Profile
GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. The company's product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease, and respiratory diseases. It also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer, and others. Wikipedia
About GlaxoSmithKline Pharmaceuticals Ltd
CEO-
Employees3.1K
FoundedNov 13, 1924
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Last report
Nov 3, 2026
Fiscal period
Q2 2027
₹19.83 / ₹16.50
+20.18%beat
Revenue / Est. (INR)
11.84B / 10.79B
+9.66%beat
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
10.41B
9.95B
9.38B
11.84B
Cost of goods sold
3.64B
3.69B
3.28B
4.44B
Cost of revenue
3.64B
3.69B
3.28B
4.44B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.52B
2.95B
1.59B
1.70B
Operating expense
3.26B
2.84B
3.31B
3.52B
Total operating expenses
6.90B
6.53B
6.59B
7.97B
Operating income
3.51B
3.43B
2.80B
3.87B
Other non operating income
321.20M
-1.09B
437.60M
727.80M
EBT including unusual items
4.00B
3.73B
3.22B
4.59B
EBT excluding unusual items
3.82B
2.94B
3.22B
4.59B
Income tax expense
1.04B
952.41M
852.70M
1.23B
Effective tax rate
26.08%
25.53%
26.44%
26.88%
Other operating expenses
1.54B
-236.82M
1.56B
1.67B
Net income
2.96B
2.78B
2.37B
3.36B
Net profit margin
28.39%
27.92%
25.27%
28.38%
Earnings per share
-
-
14.00
19.83
Interest and investment income
-
657.30M
-
-
Interest expense
-11.90M
-6.12M
-9.70M
-4.90M
Net interest expenses
-11.90M
651.18M
-9.70M
-4.90M
Depreciation and amortization charges
203.20M
131.74M
158.40M
150.20M
EBITDA
3.61B
3.52B
2.89B
4.02B
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google apps